Catalyst Funds Management Pty Ltd
Position in NBIX — Neurocrine Biosciences Inc
CIK 1896150
SYDNEY NSW, C3
Position in NBIX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$438,204
+$204,165 QoQ
Shares Held
2,600
+52.9% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#493
of 768 holders
Holding Since
Jun 2024
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Catalyst Funds Management Pty Ltd holds $2,610,858 across 5 Drug Manufacturers - Specialty & Generic names. NBIX ranks #3 (16.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
13,400 | $856,930 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
1,441 | $780,777 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
This page
|
2,600 | $438,204 | |
| 4 | AMRX |
Amneal Pharmaceuticals, Inc.
|
16,900 | $292,539 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
9,850 | $242,408 |
All Filings in NBIX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $438,204 | 2,600 | Shares | Sole | 2026-08-10 | |
| 2024-06-30 | $234,039 | 1,700 | Shares | Sole | 2024-12-18 | |
| No filing history on record for this holder in this stock. | ||||||